載入...
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. However, a substantial proportion of these patients (up to 50%) display intrinsic...
Na minha lista:
| 發表在: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7246793/ https://ncbi.nlm.nih.gov/pubmed/32370101 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21093214 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|